the cessation of capecitabine a ects the recurrence rate, but dose reduction does not.  is study presents a clinical guideline that chemotherapy using capecitabine should be continued even when the dose must be reduced because of complications. As indicated above, this study will become more meaningful if the dependences of the prognostic factors related to oncologic outcomes on dose reductio...